ArticleThe oncologist2025

Correction to: Long-term safety of selpercatinib for Rearranged during transfection (RET)-activated advanced solid tumors in LIBRETTO-001: differing patterns of adverse events over time.

No numbers read from the abstract.

Not cited yet